Galapagos(GLPG) - 2024 Q1 - Earnings Call Transcript

Operator In the past, you have mentioned that you see the CLL program as the most likely program to get fast proof of concept and get to the market. Can you provide your vision on the current progress of the program and the Thank you very much for the question. First of all, I'll speak to the program, and then secondly to the data from Bristol-Myers Squibb. With regard to our -- CLL high-risk CLL and Richter's transformation studies. The expansion part of the study is to be initiated imminently. We've had v ...